Optimind Pharma Cash Flow Statement

Financials in millions CAD. Fiscal year is March - February.

Millions CAD. Fiscal year is Mar - Feb.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May '25 May 31, 2025	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '23 Feb 28, 2023	Feb '22 Feb 28, 2022
Net Income	-0.12	-0.22	-1.4	-3.08	-0.28
Depreciation & Amortization	-	-	0.02	0.04	0.03
Asset Writedown & Restructuring Costs	-	-	0.37	1.51	-
Loss (Gain) From Sale of Investments	-	-	0.19	0.31	-
Stock-Based Compensation	0	-	0.17	0.01	0.04
Other Operating Activities	-	-	0.07	0.3	-0.13
Change in Accounts Receivable	-0.01	-0.01	0.01	-0.03	-
Change in Accounts Payable	-0.18	-0.09	0.15	-0.02	0.11
Change in Other Net Operating Assets	0	0.1	-0.05	-0.07	-0
Operating Cash Flow	-0.31	-0.21	-0.47	-1.04	-0.23
Investment in Securities	-	-	-	-0.05	-0.08
Other Investing Activities	-	-	-0.02	-0.17	-
Investing Cash Flow	-	-	-0.02	-0.22	-0.08
Long-Term Debt Issued	-	-	-	0	-
Total Debt Issued	-	-	-	0	0.41
Long-Term Debt Repaid	-	-	-0.03	-0.05	-
Total Debt Repaid	-	-	-0.03	-0.05	-0.03
Net Debt Issued (Repaid)	-	-	-0.03	-0.05	0.37
Issuance of Common Stock	0.27	0.27	-	-	1.57
Other Financing Activities	-	-	-	-	-0.14
Financing Cash Flow	0.27	0.27	-0.03	-0.05	1.8
Net Cash Flow	-0.04	0.06	-0.52	-1.31	1.49
Cash Interest Paid	-	-	-	0	-
Levered Free Cash Flow	-0.26	-0.13	-0.23	-0.72	-
Unlevered Free Cash Flow	-0.26	-0.13	-0.17	-0.67	-
Change in Working Capital	-0.19	0	0.11	-0.13	0.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.